Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment reporting

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT06037590Phase 1Completed

A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®

Role: lead

SYF2c68085913e14207bcb35b88741fd58dPhase 1Not Yet Recruiting

Comparative bioavailability study of Colistin Cyclops® administered as 3 different doses

Role: co_sponsor

All 2 trials loaded